| 1 |
29196412 | A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. | 2018 Jan 25 |
1 |
| 2 |
30045838 | A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. | 2018 Sep 13 |
2 |
| 3 |
23770776 | SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. | 2013 Aug 22 |
2 |
| 4 |
23970353 | Precision 're'arming of CD33 antibodies. | 2013 Aug 22 |
2 |